Radiolabeled Monoclonal Antibodies for the Diagnosis and Treatment of Ovarian Carcinoma

Author(s):  
Richard L. Wahl
2020 ◽  
Vol 21 (11) ◽  
pp. 1097-1102
Author(s):  
Drashti Desai ◽  
Pravin Shende

: Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells, which acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1, acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.


1987 ◽  
Vol 2 (3) ◽  
pp. 161-168 ◽  
Author(s):  
Alessandro Diotti ◽  
Olivia Santoro ◽  
Liliana Mantovani ◽  
Mario Regazzoni ◽  
Rosanna Fontanelli ◽  
...  

A double-determinant radioimmunoassay for the detection of circulating antigens associated with human ovarian carcinoma was developed using two monoclonal antibodies: MOv2 and MOv8 employed respectively as catcher and tracer. The development of the method through three different procedures enabled us to detect the presence of CaMOv2-CaMOv8 carrying molecules in 14 out of 15 ascitic fluids from ovarian carcinoma patients whose tumors were found to be positive with MOv2 and MOv8 monoclonal antibodies by immunofluorescence. Moreover, 13 out of 15 ovarian carcinoma patients presented high levels of antigen in their serum (60-170 Ua/ml). Low levels of antigen were observed in the normal population, the values ranging from 30-40 Ua/ml. However, in 13 out of 100 apparently healthy women high levels of antigen were found in the serum


1985 ◽  
Vol 30 (4) ◽  
pp. 209-214 ◽  
Author(s):  
Malaya Bhattacharya ◽  
Sunil K. Chatterjee ◽  
Aniruddha Gangopadhyay ◽  
Joseph J. Barlow

2013 ◽  
Author(s):  
Renata Maria Grifantini ◽  
Piero Pileri ◽  
Matteo Parri ◽  
Alberto Grandi ◽  
Susanna Campagnoli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document